prikaz prve stranice dokumenta Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria
  Download
PDF 105.75 KB
Scientific paper - Original scientific paper
Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria
Collegium Antropologicum, 35 (2011), 4; 1061-1066. urn:nbn:hr:105:342381
Bilić, Marija; Munjas-Samarin, Radenka; Ljubanović, Danica; Horvatić, Ivica; Galešić, Krešimir

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bilić, M., Munjas Samarin, R., Ljubanović, D., Horvatić, I. & Galešić, K. (2011). Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria . Collegium Antropologicum, 35. (4), 1061-1066. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:342381

Bilić, Marija, et al. "Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria ." Collegium Antropologicum, vol. 35, no. 4, 2011, pp. 1061-1066. https://urn.nsk.hr/urn:nbn:hr:105:342381

Bilić, Marija, Radenka Munjas Samarin, Danica Ljubanović, Ivica Horvatić and Krešimir Galešić. "Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria ." Collegium Antropologicum 35, no. 4 (2011): 1061-1066. https://urn.nsk.hr/urn:nbn:hr:105:342381

Bilić, M., et al. (2011) 'Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria ', Collegium Antropologicum, 35(4), pp. 1061-1066. Available at: https://urn.nsk.hr/urn:nbn:hr:105:342381 (Accessed 13 March 2025)

Bilić M, Munjas Samarin R, Ljubanović D, Horvatić I, Galešić K. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria . Collegium Antropologicum [Internet]. 2011 December [cited 2025 March 13];35(4):1061-1066. Available at: https://urn.nsk.hr/urn:nbn:hr:105:342381

M. Bilić, R. Munjas Samarin, D. Ljubanović, I. Horvatić and K. Galešić, "Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria ", Collegium Antropologicum, vol. 35, no. 4, pp. 1061-1066, December 2011. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:342381. [Accessed: 13 March 2025]

Metadata
Title (english)Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria
Title (croatian)Učinci ramiprila i valsartana na proteinuriju i bibrežnu funkciju u bolesnika s nedijabetičkom proteinurijom
AuthorMarija Bilić
AuthorRadenka Munjas-Samarin
AuthorDanica Ljubanović
AuthorIvica Horvatić
AuthorKrešimir Galešić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
The renin-angiotensin system is involved in the progression of chronic renal disease of both diabetic and nondiabetic origin. The angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have been demonstrated to reduce urinary protein excretion and attenuate the development of renal injury. This prospective, randomized, 12-month study assessed the effects of ramipril (N = 23) vs. valsartan (N = 22) vs. combination of ramipril and valsartan (N = 26) on proteinuria, renal function and metabolic profile in 71 patients with nondiabetic proteinuria with normal or slightly impaired renal function. Monotherapy with ramipril or valsartan and combination of these two drugs significantly reduced proteinuria, serum creatinine, cholesterol and triglycerides as well as systolic and diastolic arterial blood pressure. There was no significant difference among three study groups according to reduction of arterial blood pressure, serum cholesterol and triglycerides. At one year, a significant reduction in serum creatinine was recorded in all three study groups, whereas at 3 and 6 months a statistically significant reduction in serum creatinine was only observed in patients on combination therapy. In addition, at 3 months the reduction of proteinuria was significantly greater in patients on combination therapy than in those on either monotherapy. These results indicated the combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to be more efficacious than either monotherapy in reducing proteinuria and serum creatinine level in the first 3 (proteinuria and serum creatinine) or 6 (serum creatinine) months of treatment.
Abstract (croatian)
Reninsko-angiotenzinski sustav uključen je u progresiju i dijabetičke i nedijabetičke kronične bubrežne bolesti. Pokazalo se da inhibitori angiotenzin-konvertirajućeg enzima i blokatori receptora angiotenzina II smanjuju proteinuriju i usporavaju razvoj bubrežnog oštećenja. U ovom prospektivnom, randomiziranom, 12-mjesečnom istraživanju uspoređivani su učinci ramiprila (N=23 bolesnika), valsartana (N=22) i kombinacije ramiprila i valsartana (N=26) na proteinuriju, bubrežnu funkciju i metabolički profil u 71 bolesnika s nedijabetičkom proteinurijom s normalnom ili blago oštećenom bubrežnom funkcijom. Monoterapija ramiprilom i valsartanom i kombinacija ova dva lijeka značajno su smanjili proteinuriju, serumski kreatinin, kolesterol i trigliceride kao i sistolički i dijastolički krvni tlak. Nije bilo statistički značajne razlike između 3 skupine u smanjenju krvnog tlaka, serumskog kolesterola i triglicerida. Nakon 12 mjeseci, značajno smanjenje serumskog kreatinina zabilježeno je u sve tri skupine bolesnika, dok je nakon 3 i 6 mjeseci statistički značajno smanjenje serumskog kreatinina opaženo samo u skupini bolesnika na kombinacijskoj terapiji. Osim toga, nakon 3 mjeseca smanjenje proteinurije bilo je statistički značajno veće u skupini na kombinacijskoj terapiji, nego u skupinama bolesnika s monoterapijom ramiprilom i valsartanom. Ovi rezultati pokazuju da je kombinacijska terapija inhibitorom angiotenzin-konvertirajućeg enzima i blokatora receptora angiotenzina II učinkovitija od monoterapije u smanjenju proteinurije i serumskog kreatinina nakon 3 mjeseca i smanjenju serumskog kreatinina nakon 6 mjeseci liječenja.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCollegium Antropologicum
Numberingvol. 35, no. 4, pp. 1061-1066
p-ISSN0350-6134
URN:NBNurn:nbn:hr:105:342381
Publication2011-12
Document URLhttp://hrcak.srce.hr/file/112330
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 19:25:48